| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 4,273 | 4,641 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -18,522 | -10,793 |
| Cash and cash equivalents at beginning of period | 42,570 | - |
| Cash and cash equivalents at end of period | 24,048 | - |
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)